FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072367739> ?p ?o ?g. }

• W2072367739 endingPage "386" @default.
• W2072367739 startingPage "379" @default.
• W2072367739 abstract "To analyze the visual outcome, systemic associations, effectiveness of treatment, and predicting features of 104 scleritis patients.Retrospective case series.One hundred four patients treated for scleritis at the University Medical Centers of Groningen and Utrecht, The Netherlands.The clinical records of 104 patients diagnosed with scleritis between 1992 and 2011 at the University Medical Centers of Groningen (n = 64) and of Utrecht (n = 40) were analyzed retrospectively.Loss of visual acuity, ocular complications, related systemic disease, type of treatment, time to treatment success, and predictive features.Mean age ± standard deviation (SD) was 51.5 ± 13.6 years, and 63 (60.6 %) patients were female. Mean follow-up ± SD was 38.2 ± 33.8 months. A loss of more than 2 lines of Snellen acuity was observed in 23 patients, 3 of whom had a final visual acuity of no light perception. In general, patients with necrotizing scleritis (n = 15) had a poorer outcome. Ocular complications were observed in 88 (84.6%) patients. Underlying systemic disease was identified in 34 (32.7%) patients. Steroid-sparing immunosuppressive medication was used in 47 patients, 36 of whom were treated with methotrexate (MTX). This treatment was successful in 17 (47.2%) patients over the course of a mean ± SD of 103.7 ± 83.7 weeks. Mycophenolate mofetil was the treatment in 10 patients, and in 5 of these patients, treatment success was achieved in a mean ± SD of 65.3 ± 37.4 weeks. Treatment with tumor necrosis factor α (TNF-α) antagonists led to treatment success in a mean ± SD of 32.6 ± 21.8 weeks in 5 of the 11 treated patients. Patients with loss of visual acuity or those treated with steroid-sparing immunosuppressive drugs more often had an underlying associated disease, bilateral scleritis, and a longer duration of symptoms at presentation.Scleritis is a severe ocular inflammatory disease often associated with ocular complications. In this population, roughly half of the patients were treated with systemic immunosuppressive medication. Mycophenolate mofetil and TNF-α antagonists can be used in case of MTX failure. Tumor necrosis factor α antagonists seemed to be more effective than MTX. Within this group, an underlying associated disease, bilateral scleritis, and a longer duration of symptoms at presentation were predictive features for a more severe disease course." @default.
• W2072367739 created "2016-06-24" @default.
• W2072367739 creator A5003666086 @default.
• W2072367739 creator A5029209081 @default.
• W2072367739 creator A5046835189 @default.
• W2072367739 creator A5085645592 @default.
• W2072367739 date "2013-02-01" @default.
• W2072367739 modified "2023-10-11" @default.
• W2072367739 title "Visual Outcome, Treatment Results, and Prognostic Factors in Patients with Scleritis" @default.
• W2072367739 cites W1571149542 @default.
• W2072367739 cites W1977427854 @default.
• W2072367739 cites W1984345266 @default.
• W2072367739 cites W198593107 @default.
• W2072367739 cites W1995295340 @default.
• W2072367739 cites W1995411577 @default.
• W2072367739 cites W1995938716 @default.
• W2072367739 cites W2006699106 @default.
• W2072367739 cites W2011826792 @default.
• W2072367739 cites W2033069981 @default.
• W2072367739 cites W2041371300 @default.
• W2072367739 cites W2047512741 @default.
• W2072367739 cites W2057970527 @default.
• W2072367739 cites W2067260112 @default.
• W2072367739 cites W2069808402 @default.
• W2072367739 cites W2079706280 @default.
• W2072367739 cites W2092403539 @default.
• W2072367739 cites W2107144199 @default.
• W2072367739 cites W2116724316 @default.
• W2072367739 cites W2118101243 @default.
• W2072367739 cites W2146502982 @default.
• W2072367739 cites W2150714926 @default.
• W2072367739 cites W2159966592 @default.
• W2072367739 cites W2161446589 @default.
• W2072367739 cites W2321934992 @default.
• W2072367739 cites W4211141228 @default.
• W2072367739 doi "https://doi.org/10.1016/j.ophtha.2012.08.005" @default.
• W2072367739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23177360" @default.
• W2072367739 hasPublicationYear "2013" @default.
• W2072367739 type Work @default.
• W2072367739 sameAs 2072367739 @default.
• W2072367739 citedByCount "67" @default.
• W2072367739 countsByYear W20723677392013 @default.
• W2072367739 countsByYear W20723677392014 @default.
• W2072367739 countsByYear W20723677392015 @default.
• W2072367739 countsByYear W20723677392016 @default.
• W2072367739 countsByYear W20723677392017 @default.
• W2072367739 countsByYear W20723677392018 @default.
• W2072367739 countsByYear W20723677392019 @default.
• W2072367739 countsByYear W20723677392020 @default.
• W2072367739 countsByYear W20723677392021 @default.
• W2072367739 countsByYear W20723677392022 @default.
• W2072367739 countsByYear W20723677392023 @default.
• W2072367739 crossrefType "journal-article" @default.
• W2072367739 hasAuthorship W2072367739A5003666086 @default.
• W2072367739 hasAuthorship W2072367739A5029209081 @default.
• W2072367739 hasAuthorship W2072367739A5046835189 @default.
• W2072367739 hasAuthorship W2072367739A5085645592 @default.
• W2072367739 hasConcept C118487528 @default.
• W2072367739 hasConcept C141071460 @default.
• W2072367739 hasConcept C167135981 @default.
• W2072367739 hasConcept C195910791 @default.
• W2072367739 hasConcept C2776194053 @default.
• W2072367739 hasConcept C2778257484 @default.
• W2072367739 hasConcept C2781053147 @default.
• W2072367739 hasConcept C2781059491 @default.
• W2072367739 hasConcept C71924100 @default.
• W2072367739 hasConceptScore W2072367739C118487528 @default.
• W2072367739 hasConceptScore W2072367739C141071460 @default.
• W2072367739 hasConceptScore W2072367739C167135981 @default.
• W2072367739 hasConceptScore W2072367739C195910791 @default.
• W2072367739 hasConceptScore W2072367739C2776194053 @default.
• W2072367739 hasConceptScore W2072367739C2778257484 @default.
• W2072367739 hasConceptScore W2072367739C2781053147 @default.
• W2072367739 hasConceptScore W2072367739C2781059491 @default.
• W2072367739 hasConceptScore W2072367739C71924100 @default.
• W2072367739 hasIssue "2" @default.
• W2072367739 hasLocation W20723677391 @default.
• W2072367739 hasLocation W20723677392 @default.
• W2072367739 hasOpenAccess W2072367739 @default.
• W2072367739 hasPrimaryLocation W20723677391 @default.
• W2072367739 hasRelatedWork W1601306326 @default.
• W2072367739 hasRelatedWork W1995938716 @default.
• W2072367739 hasRelatedWork W2002120878 @default.
• W2072367739 hasRelatedWork W2047967234 @default.
• W2072367739 hasRelatedWork W2072367739 @default.
• W2072367739 hasRelatedWork W2088446335 @default.
• W2072367739 hasRelatedWork W2118496982 @default.
• W2072367739 hasRelatedWork W2439875401 @default.
• W2072367739 hasRelatedWork W2899610175 @default.
• W2072367739 hasRelatedWork W3026656749 @default.
• W2072367739 hasVolume "120" @default.
• W2072367739 isParatext "false" @default.
• W2072367739 isRetracted "false" @default.
• W2072367739 magId "2072367739" @default.
• W2072367739 workType "article" @default.